Atypical Presentations of Alzheimer Disease
Alzheimer disease (AD) is most commonly associated with an amnestic phenotype in which progressive episodic memory loss is the predominant early feature. However, a significant minority of patients — particularly those with early-onset AD (before age 65) — present with predominantly nonmemory cognitive deficits. These atypical AD variants include posterior cortical atrophy (PCA), logopenic variant primary progressive aphasia (lvPPA), dysexecutive AD, and behavioral variant AD. Each variant targets distinct functional brain networks while sharing the common underlying molecular pathology of amyloid-beta (Aβ) plaques and neurofibrillary tau tangles. Recognition of these phenotypes is essential because delays in diagnosis are common, biomarker confirmation is critical, and emerging disease-modifying therapies require accurate pathologic classification.
Bottom Line
- Four recognized atypical AD variants: Posterior cortical atrophy (PCA), logopenic variant PPA (lvPPA), dysexecutive AD, and behavioral variant AD — each with distinct clinical, imaging, and neuroanatomic signatures
- Early-onset predominance: Atypical variants are disproportionately represented in early-onset AD (before age 65), where nonmemory presentations may outnumber the classic amnestic phenotype
- Biomarkers are essential: Clinical phenotype alone cannot distinguish AD from non-AD pathology (e.g., FTLD, Lewy body disease); amyloid and tau biomarkers are required for definitive classification
- Tau PET mirrors phenotype: Regional tau deposition closely tracks the clinical variant (posterior in PCA, left temporal in lvPPA, parietal-frontal in dysexecutive AD), whereas amyloid PET is diffuse and nonspecific across variants
- Hippocampal sparing is common: Normal-appearing hippocampi on MRI should not exclude AD in patients with atypical presentations
- The term “frontal AD” is obsolete: It has been replaced by the distinct entities of dysexecutive AD and behavioral variant AD, which differ in clinical features, neuroanatomy, and management implications
Overview of Atypical AD Variants
Atypical AD variants are defined by predominant impairment in nonmemory cognitive domains at onset and early in the disease course. These variants represent the extremes of a common underlying functional spectrum of neurodegeneration, with each phenotype reflecting selective vulnerability of specific large-scale brain networks. Neuroimaging techniques — particularly FDG-PET and tau PET — reveal distinct regional abnormalities for each variant, whereas amyloid PET shows a more diffuse and overlapping distribution that is less tightly coupled to clinical phenotype.
| Feature | Typical Amnestic AD | PCA | Logopenic PPA | Dysexecutive AD | Behavioral Variant AD |
|---|---|---|---|---|---|
| Predominant deficit | Episodic memory | Higher-order visual function | Word retrieval, sentence repetition | Executive function (working memory, flexibility) | Behavior, personality, motivation |
| Typical age of onset | ≥65 years | 50–64 years | <65 years | 45–70 years | Variable |
| Peak atrophy / hypometabolism | Medial temporal, temporoparietal | Parieto-occipital, occipitotemporal | Left superior temporal, temporoparietal junction | Heteromodal association cortex (parietal > frontal) | Frontotemporal, extending to inferior temporal |
| Hippocampal involvement | Early, prominent | Relatively spared | Relatively spared | Commonly spared | Variable |
| Amyloid biomarkers | Positive | Positive | Positive (~70%) | Positive | Positive |
| Tau PET pattern | Medial temporal, widespread | Posterior occipitoparietal | Asymmetric left temporoparietal | Parietal > frontal; often highest magnitude of any AD subtype | Frontal, medial temporal, cingulate |
| Key differential diagnosis | Limbic-predominant age-related TDP-43 encephalopathy | DLB, corticobasal degeneration, prion disease | Agrammatic PPA (FTLD-tau), semantic PPA (FTLD-TDP) | Psychiatric disorders, ADHD, vascular dementia | Behavioral variant FTD |
Posterior Cortical Atrophy
Posterior cortical atrophy (PCA), originally described by Benson and colleagues in 1988, is characterized by progressive higher-order visual dysfunction with relative preservation of memory, language, executive function, behavior, and personality early in the disease course. AD is the most common underlying pathology (~80%), though PCA can also result from Lewy body disease, corticobasal degeneration, and prion disease.
Clinical Features
Patients with PCA typically present between ages 50 and 64, though late-onset cases (≥65 years) occur in up to 15% of patients. Initial symptoms are often attributed to ocular disease, leading to multiple eye examinations and prescriptions for corrective lenses before the true diagnosis is recognized.
Symptom Progression in PCA
- Year 1 (early): Blurry vision not corrected by lenses, difficulty reading (especially spreadsheets and dense text), trouble seeing items on computer screens
- Years 1–2 (intermediate): Inability to find objects in plain sight, difficulty reading traffic signs, persistent symptoms despite multiple new eyeglass prescriptions
- Year 2+ (advanced): Impaired depth perception, complete loss of reading ability, inability to sign name on a line, driving difficulties, and eventual extension to calculations, writing, and praxis
- Diagnostic delay: Patients commonly see ophthalmologists or optometrists for months to years before referral to neurology, particularly when MMSE scores are normal
Core Features and Syndromes
The 2017 consensus criteria (Crutch et al.) require at least 3 of 16 core cognitive features present as early or presenting signs. These features span two major visual processing pathways:
| Pathway | Core Feature | Associated Syndrome |
|---|---|---|
| Occipitoparietal (dorsal / “where”) | Space perception deficit | — |
| Simultanagnosia | Bálint syndrome | |
| Oculomotor apraxia | Bálint syndrome | |
| Optic ataxia | Bálint syndrome | |
| Left-right disorientation | Gerstmann syndrome | |
| Finger agnosia | Gerstmann syndrome | |
| Acalculia | Gerstmann syndrome | |
| Agraphia | Gerstmann syndrome | |
| Occipitotemporal (ventral / “what”) | Object perception deficit | — |
| Apperceptive prosopagnosia | — | |
| Alexia | — | |
| Environmental agnosia | — | |
| Both pathways | Constructional, limb, and dressing apraxia; homonymous visual field defect | — |
Classification Framework
- PCA-pure: Meets PCA criteria without other associated syndromes
- PCA-plus: Meets PCA criteria and additionally meets criteria for another syndrome (e.g., corticobasal syndrome, dementia with Lewy bodies)
- PCA-AD: PCA with confirmed AD biomarkers (CSF or amyloid PET); definite PCA-AD requires autopsy confirmation
Evaluation and Imaging
Computerized threshold visual field testing (Humphrey fields) is recommended when PCA is suspected, as homonymous defects are detected in up to 62% of patients. FDG-PET can reveal significant occipitoparietal hypometabolism even when structural MRI appears normal. The cingulate island sign (occipital hypometabolism with relative sparing of posterior cingulate metabolism) is a feature of PCA, including in the absence of Lewy body copathology.
Prognosis
All patients meeting 2017 PCA criteria will progress to dementia. Posterior functions deteriorate faster than initially spared domains, but paradoxically, global cognitive measures (e.g., MMSE) may decline more slowly than in typical AD. Median survival is approximately 8–10 years from symptom onset.
Logopenic Variant Primary Progressive Aphasia
Logopenic variant PPA (lvPPA) is characterized by impaired word retrieval leading to reduced speech fluency, with relative preservation of grammar and single-word comprehension. Of the three PPA subtypes, lvPPA has the strongest association with AD neuropathologic change, occurring in approximately 70% of cases.
Key Clinical Features of lvPPA
- Word-finding difficulty: Hesitations, pauses in spontaneous speech, and impaired confrontation naming; may be masked by circumlocution and use of simpler vocabulary
- Sentence repetition impairment: Listed as a core research criterion, though some evidence suggests it may be better classified as an ancillary feature
- Preserved grammar: Syntax and morphology remain intact, distinguishing lvPPA from agrammatic PPA
- Preserved single-word comprehension: Distinguishes lvPPA from semantic PPA
- Phonologic errors: Sound-level errors (phonemic paraphasias) during naming and speech
- Peak atrophy: Asymmetric atrophy in the language-dominant (usually left) hemisphere, including the superior temporal gyrus extending to the temporoparietal junction
- Diagnostic journey: Typically takes years rather than months due to subtle early symptoms and patient compensation strategies
PPA Subtypes Comparison
| Feature | Logopenic PPA | Agrammatic PPA | Semantic PPA |
|---|---|---|---|
| Core impairment | Word retrieval & fluency | Grammar & motor speech | Single-word comprehension |
| Repetition | Impaired (especially sentences) | May be impaired | Relatively preserved |
| Grammar | Preserved | Impaired (agrammatism) | Preserved |
| Word comprehension | Preserved | Preserved (single words) | Impaired |
| Peak atrophy | Left superior temporal / temporoparietal junction | Left inferior frontal gyrus | Left anterior temporal lobe |
| Most common pathology | AD (~70%) | FTLD-tau (~60–70%) | FTLD-TDP (~80%) |
| APOE ε4 association | Not reliably associated | Not associated | Not associated |
Risk Factors and Progression
Unlike amnestic AD, APOE ε4 is not a reliable risk factor for PPA, including the logopenic variant. A history of learning disabilities in the affected individual or first-degree family members has been demonstrated at higher frequency in PPA compared to other dementias and controls, suggesting a predisposition for vulnerability of the language network. PPA with elevated amyloid biomarkers tends to show more widespread and bilateral atrophy with earlier contralateral hemisphere involvement and greater functional decline than amyloid-negative PPA.
Dysexecutive Alzheimer Disease
Dysexecutive AD is characterized by predominant impairment in executive functions — specifically working memory, cognitive flexibility, and inhibition — with onset typically between ages 45 and 70. These patients are often still in the workforce and have parental responsibilities, making early recognition particularly consequential.
Clinical Features
The hallmark of dysexecutive AD is a striking disconnect between cognitively effortful tasks (markedly impaired) and well-learned automatic behaviors (relatively preserved). Patients struggle with multitasking, learning new software, sequential tasks (e.g., making a sandwich, assembling furniture), and mental number manipulation, while seemingly more complex but familiar activities (e.g., driving) are preserved. These difficulties are frequently misattributed to “forgetting,” leading patients and families to focus on memory rather than recognizing executive dysfunction as the primary deficit.
Diagnostic Pitfalls in Dysexecutive AD
- Psychiatric misdiagnosis: Irritability, anxiety, apathy, and poor attention arising secondary to executive dysfunction often lead to erroneous diagnoses of depression, anxiety disorders, or ADHD before the neurodegenerative etiology is recognized
- Performance validity testing failures: Executive dysfunction causes poor performance across multiple neuropsychological domains, and validity measures may falsely suggest malingering or poor effort, especially in working-age patients with job loss
- Normal hippocampi on MRI: The hippocampus is commonly spared in dysexecutive AD, potentially leading clinicians to incorrectly exclude AD from the differential diagnosis
- Normal CSF phosphorylated tau: Some patients present with normal pTau levels, necessitating additional biomarker evaluation (e.g., amyloid PET, tau PET)
- Tau PET: Dysexecutive AD commonly demonstrates the highest magnitude of tau PET signal of any AD subtype, particularly in parietal and frontal regions
Proposed Diagnostic Criteria
Recently proposed criteria for progressive dysexecutive syndrome stipulate that the behavioral variant FTD syndrome is exclusionary. Three diagnostic levels have been defined:
- Progressive dysexecutive syndrome: Persistent, predominant, progressive decline ≥6 months in core executive functions (working memory, cognitive flexibility, or inhibition) without predominant behavioral features
- Possible dysexecutive AD: Meets clinical criteria plus evidence of AD pathophysiology (decreased CSF Aβ42 or Aβ42/Aβ40 ratio; or abnormal amyloid PET)
- Definite dysexecutive AD: Meets possible criteria plus elevated CSF pTau, abnormal tau PET, autosomal dominant AD genetic variant, or postmortem confirmation of AD pathology
Behavioral Variant Alzheimer Disease
Behavioral variant AD is characterized by prominent changes in personality, social behavior, emotional responsiveness, and motivation — clinically resembling behavioral variant frontotemporal dementia (bvFTD) but caused by underlying AD pathology. Distinction from bvFTD requires biomarker confirmation.
Distinguishing Behavioral Variant AD from Dysexecutive AD
- Behavioral variant AD: Behavioral and personality changes are the primary and driving cause of functional impairment; social inappropriateness, blunted affect, apathy, and compulsive behaviors predominate
- Dysexecutive AD: Behavioral changes (irritability, anxiety, withdrawal) are secondary to the impact of executive dysfunction and are not the primary driver of dysfunction
- The obsolete term “frontal AD” should not be used, as it conflates two clinically and anatomically distinct entities
- Imaging distinction: Dysexecutive AD typically spares medial frontal regions relative to parietal/dorsolateral prefrontal regions, whereas behavioral syndromes (bvAD and bvFTD) prominently involve medial frontal, anterior temporal, and cingulate cortices
- AD biomarkers (amyloid, tau) are positive in behavioral variant AD and negative in bvFTD — this is the critical differentiator
Clinicopathologic Comparison
| Feature | Dysexecutive AD | Behavioral Variant AD | Behavioral Variant FTD |
|---|---|---|---|
| Clinical syndrome | Progressive dysexecutive syndrome; younger onset (45–70 y) | Progressive behavioral syndrome; variable age of onset | Progressive behavioral syndrome; younger onset (40–65 y) |
| Neuropsychological testing | Very abnormal; executive dysfunction affects most tests; validity testing may falsely indicate poor effort | Normal to variable memory and executive dysfunction | Normal to variable memory and executive dysfunction |
| Social, emotional, motivational features | Minor and secondary; may be absent | Major and primary; must be present | Major and primary; must be present |
| Imaging pattern | Heteromodal association cortex; parietal-dominant with frontal involvement; hippocampal sparing common | Frontotemporal extending to inferior temporal and parietal | Frontotemporal |
| AD biomarkers | Positive | Positive | Negative |
Corticobasal Syndrome Due to AD
Corticobasal syndrome (CBS) is a clinical phenotype characterized by asymmetric parkinsonism, limb apraxia, dystonia, myoclonus, and cortical sensory loss. Although traditionally associated with corticobasal degeneration (CBD), AD pathology accounts for a significant minority of CBS cases. When CBS is caused by AD, patients have positive amyloid and tau biomarkers. The overlap between PCA-plus and CBS due to AD underscores the importance of biomarker testing in patients with asymmetric cortical syndromes.
Early-Onset Alzheimer Disease
Early-onset AD (EOAD), defined as onset before age 65, accounts for approximately 5–10% of all AD cases and is disproportionately associated with atypical phenotypes. In some EOAD cohorts, nonmemory presentations may outnumber the classic amnestic phenotype.
Features of Early-Onset AD
- Higher prevalence of atypical phenotypes: PCA, lvPPA, and dysexecutive AD are overrepresented in EOAD compared to late-onset AD
- More rapid progression: EOAD often progresses faster than late-onset AD, with higher tau burden and more aggressive cortical neurodegeneration
- Genetic associations: Autosomal dominant mutations in APP, PSEN1, and PSEN2 cause familial EOAD; genetic counseling is recommended for patients with onset before age 65 and those with a strong family history, particularly first-degree relatives with younger onset
- Psychosocial impact: Patients are frequently employed, raising families, and managing complex finances; diagnostic delays are common because of the unexpected presentation at a younger age
- APOE ε4: While a risk factor for amnestic AD, APOE ε4 is not as reliably associated with atypical/aphasic variants
Diagnostic Approach
Diagnosing atypical AD requires a systematic, multimodal approach that integrates clinical assessment, neuropsychological testing, neuroimaging, and biomarker analysis. Because clinical phenotype alone cannot reliably predict underlying pathology, biomarker confirmation is indispensable.
Step-by-Step Evaluation
| Step | Modality | Purpose | Key Considerations |
|---|---|---|---|
| 1 | History & examination | Identify dominant cognitive domain; exclude nondegenerative causes | Screen for sleep disorders, medications, vascular disease, CSF dynamics disorders, psychiatric conditions |
| 2 | Neuropsychological testing | Quantify deficits, identify pattern, document severity | Performance validity testing may be falsely abnormal in dysexecutive AD; language-dependent instruments may underestimate function in PPA |
| 3 | Structural MRI | Exclude structural lesions; identify regional atrophy pattern | May appear normal early in PCA and dysexecutive AD; personally review images for subtle posterior or parietal findings |
| 4 | FDG-PET | Identify regional hypometabolism; differentiate variants | Often abnormal when structural imaging is unremarkable; cingulate island sign in PCA; parietal-dominant in dysexecutive AD |
| 5 | Amyloid biomarkers (CSF Aβ42/Aβ40 or amyloid PET) | Confirm AD pathology | CSF AD biomarkers in atypical variants are indistinguishable from typical AD; mandatory for distinguishing AD from FTLD |
| 6 | Tau biomarkers (CSF pTau or tau PET) | Support diagnosis; staging; phenotypic characterization | CSF pTau may be normal in some dysexecutive AD patients; tau PET shows variant-specific regional deposition |
| 7 | Genetic counseling | Assess for autosomal dominant causes | Recommended for all early-onset patients and those with strong family history; especially relevant for behavioral variant AD/FTD |
Neuroimaging Patterns by Variant
| Variant | Structural MRI (Atrophy) | FDG-PET (Hypometabolism) | Tau PET |
|---|---|---|---|
| Typical amnestic AD | Medial temporal, hippocampal | Temporal and parietal | Medial temporal, widespread |
| PCA | Parieto-occipital; may appear normal early | Occipitoparietal; relative frontal hypermetabolism; cingulate island sign | Posterior occipitoparietal deposition |
| Logopenic PPA | Asymmetric left superior temporal and temporoparietal | Left temporal and parietal hypometabolism | Asymmetric left temporoparietal; may show focal amyloid |
| Dysexecutive AD | Heteromodal association cortex (parietal > frontal); hippocampal sparing | Heteromodal cortex; hypermetabolism of primary sensory/motor cortices | Highest magnitude of all AD subtypes; parietal and frontal regions |
| Behavioral variant AD | Frontotemporal extending to inferior temporal and parietal | Frontal, medial temporal, and cingulate hypometabolism | Frontal and medial temporal |
Differential Diagnosis by Variant
Critical Differential Diagnoses for Atypical AD Variants
- PCA: Dementia with Lewy bodies (visual hallucinations, REM sleep behavior disorder, parkinsonism), corticobasal degeneration (asymmetric parkinsonism, alien limb), Creutzfeldt-Jakob disease (rapid course, MRI diffusion abnormalities), primary ocular disease (must be excluded by ophthalmologic examination)
- Logopenic PPA: Agrammatic PPA (FTLD-tau; impaired grammar, motor speech involvement), semantic PPA (FTLD-TDP; impaired word comprehension), stroke-based aphasia (acute onset, vascular territory distribution)
- Dysexecutive AD: Behavioral variant FTD (primary behavioral disturbance, not executive), vascular cognitive impairment (stepwise decline, vascular risk factors), primary psychiatric disorders (depression, anxiety, ADHD), normal pressure hydrocephalus (gait, urinary symptoms), medication effects
- Behavioral variant AD: Behavioral variant FTD (indistinguishable clinically; AD biomarkers are the critical differentiator), psychiatric disorders
Management Principles
Management of atypical AD variants combines pharmacologic and individualized nonpharmacologic strategies. Care must be tailored to the specific cognitive domain affected and to the unique psychosocial challenges of what is often a younger-onset dementia.
Pharmacotherapy
- Cholinesterase inhibitors and NMDA receptor antagonists: Commonly used and recommended for atypical AD, though efficacy for executive, visual, or language features has not been specifically evaluated in these phenotypes
- Anti-amyloid monoclonal antibodies: Appropriate use recommendations state that absence of data in atypical AD is not a contraindication, but this limitation should be acknowledged in shared decision-making; patients with very high tau levels (common in dysexecutive AD) may have attenuated benefit
- Symptomatic medications: Antidepressants, anxiolytics, or antipsychotics for secondary psychiatric symptoms, with vigilance against overmedication
- PCA-specific: If visual hallucinations, parkinsonism, or REM sleep behavior disorder emerge, evaluate for Lewy body copathology and manage accordingly
Nonpharmacologic Strategies
- Dysexecutive AD: Simplify environments, avoid multitasking, use checklists, capitalize on well-learned routines, address the role of anxiety in executive performance
- Behavioral variant AD: Behavioral redirection and distraction, structured routines, environmental modifications, care partner training
- PCA: Visual rehabilitation strategies, occupational therapy for activities of daily living, driving cessation counseling
- Logopenic PPA: Speech-language pathology (emerging evidence for efficacy from the Communication Bridge-2 trial); strategies addressing communication breakdowns between patients and care partners
- All variants: Care partner education, genetic counseling, social work support for disability and employment issues, referral to clinical trials, and connection to support organizations
Health Equity Considerations
Because atypical AD variants often have a younger age of onset, the diagnostic journey frequently requires years and visits to multiple clinicians. This places extraordinary demands on persistence, financial resources, and health literacy, widening access-to-care gaps for individuals from underrepresented backgrounds. AD disproportionately affects non-Hispanic Black (up to 2× risk) and Hispanic (up to 1.5× risk) older adults, yet these populations remain significantly underrepresented in research cohorts. Collaborative efforts from multisite studies, Alzheimer’s Disease Research Centers, and patient advocacy organizations are actively working to address these disparities.
References
- Jones D, Pelak V, Rogalski E. Atypical presentations of Alzheimer disease. Continuum (Minneap Minn). 2024;30(6):1614-1641.
- Crutch SJ, Schott JM, Rabinovici GD, et al. Consensus classification of posterior cortical atrophy. Alzheimers Dement. 2017;13(8):870-884.
- Townley RA, Graff-Radford J, Mantyh WG, et al. Progressive dysexecutive syndrome due to Alzheimer’s disease: a description of 55 cases and comparison to other phenotypes. Brain Commun. 2020;2(1):fcaa068.
- Graff-Radford J, Yong KXX, Apostolova LG, et al. New insights into atypical Alzheimer’s disease in the era of biomarkers. Lancet Neurol. 2021;20(3):222-234.
- Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014.
- Ossenkoppele R, Pijnenburg YAL, Perry DC, et al. The behavioural/dysexecutive variant of Alzheimer’s disease: clinical, neuroimaging and pathological features. Brain. 2015;138(Pt 9):2732-2749.
- Corriveau-Lecavalier N, Barnard LR, Bhota H, et al. Uncovering the distinct macro-scale anatomy of dysexecutive and behavioural degenerative diseases. Brain. 2024;147(4):1483-1496.
- Mesulam MM, Rogalski EJ, Wieneke C, et al. Primary progressive aphasia and the evolving neurology of the language network. Nat Rev Neurol. 2014;10(10):554-569.
- Conca F, Esposito V, Giusto G, Cappa SF, Catricala E. Characterization of the logopenic variant of primary progressive aphasia: a systematic review and meta-analysis. Ageing Res Rev. 2022;82:101760.
- McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263-269.